Stockscreener 앱 받기
53.09
2.06%
1.07
시간 외 거래:
53.54
0.45
+0.85%
전일 마감가:
$52.02
열려 있는:
$52.59
하루 거래량:
2.10M
Relative Volume:
1.21
시가총액:
$5.23B
수익:
$4.10M
순이익/손실:
$-568.53M
주가수익비율:
-8.5466
EPS:
-6.2118
순현금흐름:
$-401.18M
1주 성능:
+7.38%
1개월 성능:
+9.67%
6개월 성능:
-3.01%
1년 성능:
+22.92%
1일 변동 폭
$51.64
$55.10
1주일 범위
$49.02
$55.10
52주 변동 폭
$42.17
$78.48
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
53.09 | 5.18B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | JP Morgan | Overweight |
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Why is CRISPR Therapeutics (CRSP) down 0.7% since last earnings report? - MSN
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Eastern Progress
Understanding the Setup: (CRSP) and Scalable Risk - Stock Traders Daily
28,037 Shares in CRISPR Therapeutics AG $CRSP Bought by Blue Jean Financial LLC - MarketBeat
CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it - MSN
CRISPR Therapeutics stock is absurdly cheap -- here's why analysts see 437% upside potential - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Citizens reiterates CRISPR Therapeutics stock rating on Casgevy data By Investing.com - Investing.com Australia
Citizens reiterates CRISPR Therapeutics stock rating on Casgevy data - Investing.com
CRISPR Therapeutics AG (CRSP) advances but underperforms market: Key facts - MSN
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know - MSN
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts - Yahoo Finance
Why is Crispr Therapeutics stock gaining 3% today? By Investing.com - Investing.com Nigeria
Why is Crispr Therapeutics stock gaining 3% today? - Investing.com UK
Morgan Stanley assumes CRISPR Therapeutics stock with equalweight rating - Investing.com
Morgan Stanley assumes CRISPR Therapeutics stock with equalweight rating By Investing.com - Investing.com Canada
CRSP Stock Quote Price and Forecast - CNN
CRISPR Therapeutics AG Stock 12‑Month Price Target Cut to $81.1, Implies 64% Upside - TradingView
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Norges Bank Buys Shares of 490,206 CRISPR Therapeutics AG $CRSP - MarketBeat
Amova Asset Management Americas Inc. Sells 205,564 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
[Form 4] CRISPR Therapeutics AG Insider Trading Activity - Stock Titan
Director at CRISPR (CRSP) receives 13,000-share stock option grant - Stock Titan
CRISPR Therapeutics (CRSP) director granted 13,000 options at $51.84 strike - Stock Titan
CRISPR Therapeutics (CRSP) director awarded 13,000-share stock option grant - Stock Titan
Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02 - marketscreener.com
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - AOL.com
CRISPR Therapeutics stock (CH0334081137): Gene-editing hopes after recent updates on exa-cel and pip - AD HOC NEWS
CRISPR Therapeutics Faces Stagnant Stock Despite Promising Pipeline - Intellectia AI
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? - The Motley Fool
Eli Lilly just proved gene editing could be pharma's next gold rush -- but CRISPR Therapeutics investors should watch out - MSN
Contrarius Group Holdings Ltd Has $8.21 Million Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Capital International Investors Increases Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Why CRISPR Therapeutics (CRSP) Is Down 7.7% After Major Shelf Filing and Governance Changes – And What's Next - simplywall.st
A Look At CRISPR Therapeutics (CRSP) Valuation After Casgevy Launch And Ongoing Gene Editing Pipeline Progress - Sahm
Geode Capital Management LLC Boosts Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline - Insider Monkey
CRISPR Therapeutics stock (CH0334081137): Q1 loss and gene-editing focus shape valuation picture - AD HOC NEWS
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRISPR Therapeutics AG Amends and Restates Articles of Association – Key Updates and Company Information - Minichart
Transcript : CRISPR Therapeutics AG Presents at 46th Annual William Blair Growth Stock Conference, Jun-03-2026 04 - marketscreener.com
CRISPR Therapeutics (NASDAQ: CRSP) investors approve 2026 plan and capital changes - Stock Titan
CRISPR Therapeutics Jumps 12% in New York Trading - TechStock²
CRSP Stock Climbs As Wall Street Lifts Price Targets - StocksToTrade
Stock Traders Buy High Volume of CRISPR Therapeutics Call Options (NASDAQ:CRSP) - MarketBeat
CRSP Stock Climbs As Wall Street Nudges Price Targets Higher - timothysykes.com
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
크리스퍼 테라퓨틱스 주식 (CRSP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 23 '26 |
Sale |
46.78 |
3,182 |
148,854 |
94,308 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 23 '26 |
Sale |
46.78 |
10,020 |
468,736 |
255,501 |
| Prasad Raju | Chief Financial Officer |
Mar 23 '26 |
Sale |
46.78 |
3,708 |
173,460 |
15,565 |
| Patel Naimish | Chief Medical Officer |
Mar 16 '26 |
Sale |
48.26 |
3,150 |
152,019 |
13,143 |
| Prasad Raju | Chief Financial Officer |
Mar 16 '26 |
Sale |
48.26 |
9,869 |
476,278 |
13,773 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 16 '26 |
Sale |
48.26 |
3,450 |
166,497 |
91,240 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 16 '26 |
Sale |
48.26 |
10,349 |
499,443 |
245,834 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 11 '26 |
Sale |
52.80 |
2,800 |
147,840 |
87,815 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '26 |
Sale |
52.80 |
9,798 |
517,334 |
235,558 |
| Kulkarni Samarth | Chief Executive Officer |
Feb 19 '26 |
Sale |
52.58 |
6,967 |
366,325 |
226,106 |
2.60%
0.94%
자본화:
|
볼륨(24시간):